Akari Therapeutics company info

What does Akari Therapeutics do?
Akari Therapeutics (NASDAQ:AKTX) is a biopharmaceutical company engaged in the development of treatments for various autoimmune and inflammatory diseases. The company focuses on leveraging its innovative drug development platform to create therapies that address critical unmet medical needs, particularly in areas where inflammation plays a key role in disease progression. Akari's lead product candidate, nomacopan, is in various stages of clinical trials targeting conditions such as paroxysmal nocturnal hemoglobinuria (PNH), atopic keratoconjunctivitis, and bullous pemphigoid. Akari's objectives are to advance the clinical development of its pipeline products, secure regulatory approvals, and ultimately improve patient outcomes in diseases with significant inflammatory components.
Akari Therapeutics  company media
Company Snapshot

Is Akari Therapeutics a public or private company?

key
Ownership
Public

How many people does Akari Therapeutics employ?

people
Employees
9

What sector is Akari Therapeutics in?

pie chart
Sector
Health Care

Where is the head office for Akari Therapeutics ?

location pin
Head Office
Boston, United States

What year was Akari Therapeutics founded?

founded flag
Year Founded
2004
What does Akari Therapeutics specialise in?
/Biopharmaceutical Company /Rare Diseases /Autoimmune Conditions /Inflammatory Diseases /Nomacopan Development /Clinical Trials

What are the products and/or services of Akari Therapeutics ?

Overview of Akari Therapeutics offerings
Nomacopan (Coversin), a complement C5 inhibitor aimed at treating paroxysmal nocturnal hemoglobinuria and other complement-driven diseases.
A Phase III clinical trial for pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA), addressing a significant unmet medical need in stem cell transplant recipients.
Development of PAS-nomacopan, a long-acting version of nomacopan, designed to enhance patient compliance and extend the duration of therapeutic effects.
Research into treating Geographic Atrophy (GA) secondary to Age-related Macular Degeneration (AMD) with nomacopan, exploring the role of complement in chronic diseases of the eye.
Investigation into the efficacy of nomacopan for treating Bullous Pemphigoid (BP), a rare, chronic autoimmune skin disorder.
A study on the use of nomacopan in treating atopic keratoconjunctivitis (AKC), offering potential relief for patients with severe eye allergies.

Who is in the executive team of Akari Therapeutics ?

Akari Therapeutics leadership team
  • Ms. Rachelle Suzanne Jacques
    Ms. Rachelle Suzanne Jacques
    President, CEO & Director
  • Ms. Wendy F. DiCicco CPA
    Ms. Wendy F. DiCicco CPA
    Interim Chief Financial Officer
  • Ms. Melissa  Bradford-Klug
    Ms. Melissa Bradford-Klug
    Chief Operating Officer
  • Dr. Miles  Nunn
    Dr. Miles Nunn
    Chief Scientific Officer
  • Dr. John F. Neylan III, M.D.
    Dr. John F. Neylan III, M.D.
    Executive VP & Chief Medical Officer